About OncoSynergy

Guiding Principles

We put patients first

We are physicians interested in durable outcomes and cures

Cancer biology is highly complex

Monotherapies will always result in resistance

Synergistic combinations are the key to durable responses

Should include a resistance inhibitor and an immunotherapy

Company Overview

The vision of OncoSynergy, a UCSF spin-out, is to radically improve outcomes for cancer patients with gravely underserved needs particularly glioblastoma, the most common and malignant primary brain cancer.

Our intent is to develop transformative, multi-indication, platform drugs that change the standards of care, with the goal of providing durable outcomes and cures for patients. We will leverage corporate partnerships and enhanced Food and Drug Administration programs to expedite programs to market. To date, OncoSynergy has been awarded two Orphan Drug Designations by the FDA Office of Orphan Products Development including in the treatment of glioblastoma.

Founders

Shawn Carbonell, MD, PhD
Founder, CEO & Chief Scientific Officer 

Dr. Carbonell received his MD and PhD (Neuroscience) from the University of Virginia NIH-funded Medical Scientist Training Program (MSTP) where he was a Dean’s Merit Scholar. He started neurosurgery residency at Cedars-Sinai Medical Center in 2009. Prior to founding OncoSynergy, he completed two postdoctoral Fellowships in neuro-oncology at the University of Oxford and UCSF.

Anne-Marie Carbonell, MD
Founder & Acting Chief Medical Officer 

Dr. Carbonell received her BS in biochemistry, summa cum laude and with an honors in research, from the University of Missouri, Columbia. She graduated AOA and ranked #1 from St. Louis University Medical School. In 2009, she started neurosurgery residency at the Cleveland Clinic. Before joining OncoSynergy, Dr. Carbonell lead clinical development at a neurosurgical device company.

Catherine Park, MD
Founder

Dr. Park is Professor and Chair of the Department of Radiation Oncology, at the University of California at San Francisco (UCSF). She received her medical degree from the UCLA Geffen School of Medicine and completed her residency at Harvard University’s Beth Israel Hospital. Dr. Park is Principal Investigator of an NIH-funded oncology laboratory studying the role of CD29 in radioresistance.

Scientific Advisory Board

Mina Bissell, PhD 

Dr. Bissell is a pioneer studying the critical role of the tumor microenvironment and is a Distinguished Scientist at Lawrence Berkeley National Laboratory. She is the 2016 E.B. Wilson Medal awardee from the ASCB. Dr. Bissell gave an acclaimed TEDMed talk in 2012 highlighting her discoveries with nearly one million views.

Rick Horwitz, PhD

Dr. Horwitz is the founding Executive Director of the Paul Allen Institute for Cell Science. He identified the the first fibronectin receptor leading to the discovery of the integrin family of adhesion and signaling receptors. He was a co-founder of and lead the Cell Migration Consortium supported by a decade of NIH funding.

Caroline Damsky, PhD

Dr. Damsky is a pioneer in the study of integrins beginning her studies in the laboratory of Clayton Buck at the Wistar Institute. Later, at UCSF, she developed some of the first monoclonal antibodies against human integrin receptors. She is Professor Emeritus and former Assoc. Dean of Academic Affairs, UCSF.

Jean Pierre Bizzari, MD

Dr. Bizzari was the former Global Head of Oncology at Celgene. He is a 25-year veteran of the biopharma industry who led the clinical development and FDA approval of several cancer drugs including TAXOTERE®, ELOXATIN®, ABRAXANE® & IRINOTECAN®, as well as the glioblastoma therapies fotemustine and GLIADEL®.

Pamela Munster, MD

Dr. Munster, herself a cancer survivor, is Professor of Medical Oncology at the University of California at San Francisco. She is the Director of the UCSF Early Phase Clinical Trials Unit; Co-Leader of the UCSF Center for BRCA Research; and Leader of the UCSF Experimental Therapeutics Program.

M. Sean Grady, MD

Dr. Grady is a Board Certified neurosurgeon and the Charles Harrison Frazier Professor and Chairman of Neurosurgery at the University of Pennsylvania Perelman School of Medicine. He is the author of over 150 peer reviewed papers and 5 patents and a Co-Founder of the medical device company, Stereotaxis, Inc.

Manish Aghi, MD, PhD

Dr. Aghi is a Board Certified neurosurgeon and Professor of Neurological Surgery at the University of California at San Francisco. He received his dual degrees and trained in neurosurgery at Harvard Medical School. Dr. Aghi leads a NIH-funded laboratory focused on glioblastoma at the UCSF Brain Tumor Research Center.

Board of Directors

Shawn Carbonell, MD, PhD

CEO & Chief Scientific Officer 

Robert Dunkle

President and CEO, A.B.E.S. Partners

Allen Salmasi

CEO and Chairman, NLABS, Inc.

Hen-Suh Park, PhD

Founder and Chairman, KICC, Ltd.